References
Bleumer I, Oosterwijk E, de Mulder P, Mulders PF (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65–75
Oosterwijk E, Ruiter DJ, Hoedemacker PJ, Pauwels, EK, Jonas U, Zwartendijk J, Warnaar SO (1986) Monoclonal antibody G 250 Recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 15–10–38:489–494
Steffens MG, Boerman, OC, De Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E (1999) Phase I Radioimmunotherapy of metastatic renal cell carcinoma with131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5 [Suppl 10]:3268s–3274s
Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM (2002) Anti-Renal cell carcinoma chimeric antibody G250. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 51:171–177
Conflict of interest:
No information supplied.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mulders, P., Bleumer, I., Debruyne, F. et al. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IXG250/MN . Urologe 43 (Suppl 3), 146–147 (2004). https://doi.org/10.1007/s00120-004-0609-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-004-0609-3